

# **Certificate of Analysis**

Print Date: Nov 19th 2021

Batch No.: 2

www.tocris.com

Catalog No.: 5764

**Product Name: Deferoxamine mesylate** 

CAS Number: 138-14-7

**IUPAC Name:**  $N^4$ -[5-[[4-[[5-(Acetylhydroxyamino)pentyl]amino-1,4-dioxobutyl]hydroxyamino]pentyl]- $N^1$ -(5-aminopentyl)

-N<sup>1</sup>-hydroxybutanediamide methanesulfonate

### 1. PHYSICAL AND CHEMICAL PROPERTIES

 $C_{25}H_{48}N_6O_8.CH_4O_3S.$ **Batch Molecular Formula:** 

**Batch Molecular Weight:** 656.79 **Physical Appearance:** White solid

water to 100 mM Solubility: Store at -20°C Storage:

**Batch Molecular Structure:** 

#### 2. ANALYTICAL DATA

<sup>1</sup>H NMR: Consistent with structure Mass Spectrum: Consistent with structure

Microanalysis: Carbon Hydrogen Nitrogen

> Theoretical 47.55 7.98 12.8 Found 47.54 7.82 12.89

www.tocris.com/distributors Tel: +44 (0)1235 529449 Tel:+1 612 379 2956



## **Product Information**

Print Date: Nov 19th 2021

Batch No.: 2

www.tocris.com

**Product Name: Deferoxamine mesylate** 

CAS Number: 138-14-7

IUPAC Name:  $N^4$ -[5-[[4-[[5-(Acetylhydroxyamino)pentyl]amino-1,4-dioxobutyl]hydroxyamino]pentyl]- $N^1$ -(5-aminopentyl)

-*N*<sup>1</sup>-hydroxybutanediamide methanesulfonate

#### **Description:**

Deferoxamine mesylate is an iron chelator. Also hypoxia mimetic and inhibitor of ferroptosis. Has neuroprotective effects in animal models of stroke, traumatic brain injury and neurodegenerative diseases.

#### **Physical and Chemical Properties:**

Batch Molecular Formula: C<sub>25</sub>H<sub>48</sub>N<sub>6</sub>O<sub>8</sub>.CH<sub>4</sub>O<sub>3</sub>S.

Batch Molecular Weight: 656.79 Physical Appearance: White solid

#### **Batch Molecular Structure:**

**Storage:** Store at -20°C. This product is packaged under an inert atmosphere.

Catalog No.: 5764

#### Solubility & Usage Info:

water to 100 mM

#### Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. Our standard recommendations are:

SOLIDS: Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

SOLUTIONS: We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

#### References:

Kosyakovsky et al (2019) Quantifying intranasally administered deferoxamine in rat brain tissue with mass spectrometry. ACS Chem.Neurosci. 10 4571. PMID: 31573798.

**Chau** *et al* (2005) Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1alpha induction in response to hypoxic stress and growth factors. Cancer Res. *65* 4918. PMID: 15930314.

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use